Skip to main content

Dr Reddys Laboratories Ltd 6-K, filed Nov 5, 2026

Dr Reddys Laboratories Ltd (RDY)

6-K 2026-11-05 For: 2026-11-05
View Original
Added on November 05, 2026

About this 6-K

Dr Reddys Laboratories Ltd filed this 6-K on November 5, 2026.

Dr. Reddy’s Laboratories Ltd. said Brazil’s National Health Surveillance Agency (ANVISA) granted marketing authorization for generic semaglutide injection for adults with insufficiently controlled type 2 diabetes mellitus. The company plans to launch the once-weekly treatment in Brazil with Aché. AI summary